May 11, 2022 / 03:00PM GMT
Elizabeth Schneider - NanoString Technologies, Inc. - Senior Global Marketing Manager
Hello, everyone. Welcome to another NanoString Webinar Presentation on Oncology Research. My name is Elizabeth Schneider, Senior Global Marketing Manager here at NanoString. Today, we have the pleasure of speaking Dr. Alexandre Hirayama. He is a Research Associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center. And his presentation today is going to be on understanding the efficacy of CAR-T cell therapy for large B-cell lymphoma.
A little bit about Alexandre. He is an acting instructor in the Department of Medicine at the University of Washington School of Medicine and an attending physician of the Seattle Cancer Care Alliance. He joined Fred Hutch in July of 2017 to train as a physician scientist in the clinical research division laboratory of Dr. Cameron Turtle and he has worked on elucidating factors impacting outcomes of CD19-targeted CAR-T cell therapy for adults with B-cell malignancies.
We will be having a Q&A at the end of the session. For those of you who are
NanoString Technologies Inc to Discuss the Efficacy of CAR-T Cell Therapy for LBCL Transcript
May 11, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers